London, UK; Brentwood, TN, US; 27 August 2008 - Protherics PLC
("Protherics" or the "Company"), the international biopharmaceutical
company focused on critical care and cancer, today
announces the initiation of a phase 2a proof-of-concept study of
ProlarixTM, a targeted prodrug chemotherapy being developed for the
treatment of primary liver cancer (hepatocellular carcinoma or "HCC").
This follows promising data from a phase 1 study of Prolarix, presented
at the American Society of Clinical Oncology (ASCO) Annual Meeting
in Chicago, USA on 2 June 2008.
